Gilead guides to slight decline in 2016 revenues

• Gilead Sciences (NASDAQ:GILD) is now up 0.5% in postmarket trading after its solid earnings. For 2016, Gilead expects slightly smaller net product sales, of $30B-$31B, with a product gross margin of 88-90%.
• R&D expenses are seen coming at $3.2B-$3.5B, with SG&A coming in at $3.3-$3.6B.
• Effective tax rate is expected at 18-20%, with expected impacts to EPS (from acquisition, stock-based compensation etc.) to be $1.10-$1.16.
• Conference call to come at 4:30 p.m. ET.
• Previously: Gilead Sciences declares $0.43 dividend (Feb. 02 2016)
• Previously: Gilead gains on Q4 beat; raises dividend, sets $12B buyback (Feb. 02 2016)
• Previously: Gilead Sciences beats by $0.32, beats on revenue (Feb. 02 2016)